Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Elicio Therapeutics ( (ELTX) ) has issued an update.
On May 19, 2025, Elicio Therapeutics, Inc. held its annual meeting of stockholders, where two key proposals were voted on. The stockholders elected Karen Wilson and Robert R. Ruffolo, Jr., Ph.D., FCPP, as directors for three-year terms and ratified the appointment of Baker Tilly US, LLP as the company’s independent registered public accounting firm for the fiscal year ending 2025.
The most recent analyst rating on (ELTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Elicio Therapeutics stock, see the ELTX Stock Forecast page.
Spark’s Take on ELTX Stock
According to Spark, TipRanks’ AI Analyst, ELTX is a Underperform.
Elicio Therapeutics faces significant financial challenges, with negative revenue growth and poor margins being the primary concerns. Technical analysis indicates bearish momentum, while the valuation aspect shows limited appeal. However, recent positive corporate events, such as leadership changes and clinical advancements, provide some optimism for future potential, albeit with high risk.
To see Spark’s full report on ELTX stock, click here.
More about Elicio Therapeutics
Average Trading Volume: 38,785
Technical Sentiment Signal: Sell
Current Market Cap: $93.42M
For an in-depth examination of ELTX stock, go to TipRanks’ Stock Analysis page.